Efficacy and Safety of Polymer-free Amphilimus-eluting Stent According to the Diabetes

Last updated: April 3, 2024
Sponsor: Korea University Anam Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Coronary Artery Disease

Atherosclerosis

Vascular Diseases

Treatment

Cre8™/Cre8™ EVO drug-eluting stent

Clinical Study ID

NCT05759676
CRE8DM
  • Ages > 19
  • All Genders

Study Summary

Drug-eluting stents (DES) have been found to reduce the rate of stent restenosis compared to bare metal stents (BMS), but the first generation DES caused an increase in stent thrombosis. The second generation DES, including the Cre8Evo stent, has been designed to address these issues. The Cre8Evo stent is made of cobalt chromium and releases the drug amphilimus into the vessel wall, which is quickly absorbed and then lost, creating a BMS-like form. The Cre8Evo stent does not contain polymers and does not induce an inflammatory response. It inhibits cdk2 and RhoA, reducing the proliferation and migration of vascular smooth muscle cells. In diabetic patients, the Cre8Evo stent showed superior results in suppressing late proliferation compared to conventional DES. The Cre8Evo stent has been found to be safe and effective in clinical studies, and it has a superior effect in the clinical course of diabetic patients compared to other stents. The purpose of the study is to evaluate the effectiveness and safety of the Cre8Evo stent in actual clinical practice, specifically comparing outcomes in patients with and without diabetes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 19 or older
  • Patients who agreed to the research protocol and clinical follow-up plan,voluntarily decided to participate in this study, and gave written consent to theconsent form ③ Patients who underwent coronary angioplasty by inserting Cre8™ orCre8™ EVO stent for coronary artery disease for a lesion confirmed within thelast 1 month

Exclusion

Exclusion Criteria:

  • Patients with known hypersensitivity or contraindications to the following drugs orsubstances: heparin, aspirin, clopidogrel, amphilimus, cobalt chrome, stainless steelnickel, 316L metal, and contrast media If it can be controlled by pheniramine andpheniramine, registration is possible, but if there is known anaphylaxis, it isexcluded.)
  • Pregnant women, lactating women, or women of childbearing age who are planning tobecome pregnant during the study period ③ Patients who are planning surgery tostop antiplatelet drugs within 12 months from registration
  • Patients whose remaining life expectancy is expected to be less than 1 year
  • Patients who visited the hospital due to cardiogenic shock and arepredicted to have a low survival rate based on medical judgment ⑥Subjects participating in medical device randomization research ⑦Patients who underwent surgery using a stent other than Cre8™/Cre8™ EVOat the time of registration

Study Design

Total Participants: 1800
Treatment Group(s): 1
Primary Treatment: Cre8™/Cre8™ EVO drug-eluting stent
Phase:
Study Start date:
March 09, 2023
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Korea University Anam Hospital

    Seoul, 136-705
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.